Greenwich LifeSciences, Inc. GLSI
14.94 USD -0.34 (-2.23%)
Regular-session close
15.61 +0.67 +4.48%
After hours · Nov 13, 7:50 PM ET
14.56 Day range 15.87
7.85 52-week range 33.56
- YTD
- -28.89%
- 1 year
- +82.20%
News
benzinga.com Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027 Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69 HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $50 to $69.
benzinga.com Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification.FLAMINGO-01 Steering Committee Clinical StrategyOn…- benzinga.com Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
benzinga.com Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial All European and US Sites to Treat Patients with Commercially Manufactured GP2The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023…- benzinga.com Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.31) by 87.1 percent. This is a 4.92 percent increase over losses…
benzinga.com Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026 from the ASCO Annual Meeting 2026.The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's…
benzinga.com Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Greenwich LifeSciences Receives Nasdaq Noncompliance Notice Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast…
benzinga.com Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.- benzinga.com Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
- benzinga.com Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Greenwich Lifesciences' Preliminary Update Shows A Continued Reduction In The Recurrence Rate In The Fully Enrolled, 250-patient, Open-label Non-HLA-A*02 Arm Of FLAMINGO-01 Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…- benzinga.com Greenwich LifeSciences Says FDA Approves The First Commercial Lot Of GP2 Vials For Use In FLAMINGO-01 Study In U.S. STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,…
- benzinga.com Greenwich LifeSciences Says Cash on Hand Can Cover 2026 as Breast Cancer Trial Advances Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday 
benzinga.com Greenwich LifeSciences Stock Jumps After FDA Update Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for…- benzinga.com Market-Moving News for January 22nd BABA: 5% | Alibaba shares are trading higher on Bloomberg report of company moving toward IPO of its in-house AI chipmaking unit, T-Head. GLSI: 65% | Greenwich LifeSciences Says FDA Clears First…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Greenwich LifeSciences Says FDA Clears First Commercial GP2 Lot for Phase III Breast Cancer Trial Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
benzinga.com Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
benzinga.com CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday - benzinga.com HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $50 HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $39 to $50.
benzinga.com What's Going On With Greenwich LifeSciences Stock Monday? Greenwich LifeSciences shares are trading higher Monday after the company announced it extended its lock-up period to Sept. 30, 2026.
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com What's Going On With Greenwich LifeSciences Friday? Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streamlining its Phase 3 FLAMINGO-01 trial.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 1214 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 211 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's morning trading, 400 companies set new 52-week lows.
- benzinga.com 51 Biggest Movers From Friday Gainers
- benzinga.com 38 Stocks Moving In Friday's Mid-Day Session Gainers
- benzinga.com 35 Stocks Moving in Monday's Pre-Market Session Gainers Teligent, Inc. (NASDAQ: TLGT) rose 74.4% to $1.10 in pre-market trading after declining over 8% on Friday. A Special Meeting of Stockholders is scheduled to reconvene on Wednesday December 16.
- benzinga.com 84 Biggest Movers From Yesterday Gainers
- benzinga.com 60 Stocks Moving In Thursday's Mid-Day Session Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner,
- benzinga.com 70 Biggest Movers From Yesterday Gainers Greenwich Lifesciences Inc (NASDAQ: GLSI) shares jumped 998.1% to close at $57.10 on Wednesday after the company reported data showing 0% breast cancer recurrences following surgery and…
- benzinga.com 4 Sectors Moving Down In Tuesday's Intraday Session Here is the sector-by-sector list of stocks moving lower in today's intraday session: